Patients with psoriasis, in particular those requiring systemic treatment, tend to be above normal weight. Obesity is associated with psoriasis and contributes significantly to the increased cardiovascular risk in these patients. Most biologics used to treat psoriasis in the European Union are fixed dosed treatments: etanercept, adalimumab and ustekinumab. Apart from infliximab, dosing regimens do not account for weight, with the exception of ustekinumab, the dose of which should be doubled in patients weighing more than 100 kg. The aim of this study was to review the available evidence on the ...
Obesity and psoriasis: body weight and body mass index influence the response to biological treatment is a post from: Skincare
Obesity and psoriasis: body weight and body mass index influence the response to biological treatment via BuzzBlazer.com
No comments:
Post a Comment